DAX22.163 -1,3%ESt505.248 -1,6%Top 10 Crypto11,79 -1,8%Dow42.076 +1,2%Nas17.296 -0,2%Bitcoin76.552 +0,6%Euro1,0818 -0,1%Öl74,74 +1,9%Gold3.122 +1,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 HENSOLDT HAG000 Volkswagen (VW) vz. 766403 thyssenkrupp 750000 Novo Nordisk A3EU6F Amazon 906866 Siemens Energy ENER6Y BYD A0M4W9 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Trump-Zölle im Fokus: DAX schließt in Rot -- US-Börsen uneins -- BYD stärkt Europa-Vertrieb -- Chip-Aktien um NVIDIA und Infineon brechen ein -- HENSOLDT, Tesla, Microsoft, RWE, CANCOM im Fokus
Top News
Tesla-Aktie schwach: Anhaltende Proteste gegen Tesla und Elon Musk Tesla-Aktie schwach: Anhaltende Proteste gegen Tesla und Elon Musk
Darum tritt der Euro auf der Stelle Darum tritt der Euro auf der Stelle
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Amgen Aktie

NeuKaufenVerkaufen
Amgen Aktien-Sparplan
288,40 EUR +6,15 EUR +2,18 %
STU
312,33 USD +5,38 USD +1,75 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.152,30 Mrd. EUR

KGV34,48Div. Rendite3,45%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN867900

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS0311621009

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAMGN

Amgen Aktien News

DatumMeistgelesen
PR NewswireAMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 CREDIT SUISSE GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
PR NewswireAMGEN TO WEBCAST INVESTOR CALL AT AHA 2022
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 THIRD QUARTER FINANCIAL RESULTS
PR NewswireAMGEN ANNOUNCES 2022 FOURTH QUARTER DIVIDEND
PR NewswireAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
PR NewswireAMGEN'S ANNUAL TRENDS REPORT FINDS COMPETITION CREATED BY BIOSIMILARS CONTRIBUTED $21 BILLION IN U.S. HEALTHCARE SYSTEM SAVINGS
PR NewswireAMGEN OPENS NEW STATE-OF-THE-ART RESEARCH AND DEVELOPMENT LABORATORY SITE IN SAN FRANCISCO BAY AREA
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
PR NewswireLUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
PR NewswireLUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
PR NewswireAMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
PR NewswireAMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022
PR NewswireNEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
PR NewswireAMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
PR NewswireAMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS
PR NewswireAMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022
PR NewswireAMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS
PR NewswireAMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
PR NewswireAMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
PR NewswireAMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS
PR NewswireAMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND
PR NewswireAMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS
PR NewswireAMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM
PR NewswireAMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE
PR NewswireFDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
PR NewswireNEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTA...
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE
PR NewswireAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
PR NewswireNEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022
PR NewswireAMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE
Wer­bung

Amgen News

Amgen News: auf dieser Seite finden Sie alle Amgen News und Nachrichten zur Amgen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Amgen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Amgen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.